This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Conclusions from the meeting of the special European Council (17-18 April 2024) have recognised a need for new European competitiveness deal “anchored in a fully integrated Single Market”. The post Enhancing competitiveness of European life sciences appeared first on European Pharmaceutical Review.
The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development. Insulin prices have long been a pain point for diabetics.
What’s more, your highest revenue service lines are likely already facing stiff competition from all angles. . For these reasons and more, it’s imperative to identify your unique selling propositions, review them, and revise them regularly to remain competitive. . So, how can your brand stay competitive? The answer is twofold.
New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.
to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.
The Association of the British Pharmaceutical Industry (ABPI) has drawn attention to a new report , which has emphasised the importance of UK advanced manufacturing requiring a long-term strategy to ensure its continued success. Article: Are we globally prepared for the next pandemic?
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP. It’s not all bad news.
According to UK Research and Innovation ( UKRI ), £13 million is set to fund medicine manufacturing in the UK, through a focus on innovation in intracellular drug delivery, digitalisation and automation and nucleic acid medicines. Seventeen new projects from the Innovate UK Transforming Medicine Manufacturing programme will benefit.
Washington State University researchers have developed a centrifugal bioreactor that is able to manufacture T cells, at 95 percent of the maximum growth rate — about 30 percent quicker than current technologies. I really hope having novel technologies to help with manufacturing reduces that financial barrier for these life-saving therapies.”
While maintaining a healthy manufacturing industry for production of ‘high tech’ pharmaceuticals, Europe has stepped away from manufacturing essential medicines and active pharmaceutical ingredients (APIs) due to unrelenting price pressures and is now heavily reliant on the import of these critical ingredients.
According to Medicines for Europe, the Munich District Court’s Supplementary Protection Certificate (SPC) manufacturing waiver , issued in Germany in October 2023, is “in conflict” with the objectives of the waiver. ” This threatens investments in manufacturing, according to Medicines for Europe.
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), more than 600 essential medicines are at risk if a proposed restriction on the use of fluorinated substances, per- and polyfluoroalkyl substances (PFAS) across pharmaceutical manufacturing in the EEA, is implemented.
The pharmaceutical industry is becoming increasingly conscious of emissions and the importance of sustainable manufacturing. 1 Every major pharmaceutical manufacturer in the UK and Ireland is investing in making their operations and supply chains more environmentally friendly.
To address these issues, companies should adopt more advanced production strategies such as continuous flow chemistry, as they can shorten manufacturing processes, increase productivity and throughput. These insights help to drive highly efficient manufacturing processes, ensuring competitive product delivery on time and within budget.
percent of biopharmaceutical companies outsource at least some of their activities, which has helped make biopharmaceutical contract manufacturing a $14 billion industry. The investigators foresee a highly promising and profitable future for biopharmaceutical contract development and manufacturing organisations (CDMOs) over the next decade.
A deep carbon footprint is a common hallmark of energy intensive manufacturing processes – and the manufacture of pharmaceuticals is no exception. The four governments of the UK established the scheme to increase the climate ambition of the UK’s carbon pricing policy, whilst also protecting the competitiveness of UK businesses.
On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. This is important due to the UK’s currently limited short-scale manufacturing capacity.
In the interview, conducted at CPHI Barcelona, Krishna Venkatesh, Global Head, Sterile Manufacturing Operations at Dr Reddy’s Laboratories explores industry’s growing focus on achieving end-to-end connectivity, as well as the potential of automation and track and trace solutions. KV : We have seen two specific elements.
That’s good news for Bristol Myers Squibb, which has secured a few more competition-free months for its aging leukemia blockbuster Sprycel. . | With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely.
o find out about the current trends in cell and gene therapy manufacturing, EPR spoke to Cell and Gene Therapy Catapult (CGT Catapult)’s Chief Manufacturing Officer, Stephen Ward, and Chief Business Officer, Jeanette Evans. Licensing of the manufacturing suites is expected in early 2024. So now we have a really nice blend.”
Pharmaceutical manufacturers and distributors work together in a robust system to deliver high-quality products, but drug manufacturing and distribution have become increasingly complex in recent years. Outsourcing, which has become mainstream in pharma, has also led to competition that doesn’t always benefit patients.
. | Pfizer mused on ADC opportunities in China, while Takeda's R&D head revealed details behind the company's competitive TYK2 deal with Nimbus at this year's J.P. Astellas received a manufacturing-related rejection for its gastric cancer candidate. Morgan Healthcare Conference. And more.
Expirations of biologic patents has enabled manufacturers to enter the market and offer lower-cost alternatives of these drugs, according to the report. This has resulted in “increased competition and price pressure, driving the growth of the biosimilar market”. million by 2032, at 17.6 percent CAGR between 2023 and 2032.
Key areas included in the Political Guidelines Increasing competitiveness Harnessing innovation–covering digital, collaboration, strategy and more—was conveyed as a vital component for improving European competitiveness. As such, she noted that the initial priority will be “prosperity and competitiveness.”
These platforms need to replace traditional data management methods and workflows for biopharma companies and contract development and manufacturing organizations that seek competitive advantages. Cloud-based data management solutions help the industry meet its business and compliance challenges.
From automation and Artificial Intelligence (AI) to Blockchain and advanced analytics, these technologies offer unprecedented opportunities to enhance data integrity throughout the manufacturing lifecycle. The importance of data integrity in Biopharma Data integrity is critical in Biopharma and a source of strong competitive advantage.
To optimise autoinjector combination product development, it is crucial for pharma and biotech to partner with device companies that have in-house control over the whole device manufacturing process.
High drug prices preferentially benefit the largest drug manufacturers, which spend only about 10 to 20 percent of their revenue on research and development — far less than they spend on marketing, administration, and stock buybacks and dividends. With that late-stage investment comes control of the lucrative patents on these products.)
Despite China producing a significant proportion of the world’s API supply (mostly small molecule), it manufactures relatively few biosimilar and innovator drugs and no cell and gene therapies for the western markets of Europe and the US despite investments and an increasing number of startups to improve innovative manufacture.
Pfizer and Merck have chosen to designate a select few generic manufacturers to produce cheaper versions of their drugs through the Medicines Patent Pool (MPP). For less wealthy nations, competition isn’t even a possibility. Reportedly, the cost of production for molnupiravir stands at about $17.74.
Advancements in manufacturing technology, plus availability of cost-effective treatment options are also influencing the sector. This can restrict a manufacturer’s capacity to make income. Other molecule types Small molecule API manufacturers are in fierce competition with medicines such as biologics, the report stated.
As a healthcare manufacturer you are responsible for making sure the products you sell are of high quality and that the people who buy them know what to do with them. It is also important to understand how digital strategies can help your company grow, improve your customer service, and maintain a competitive edge in today's market.
In pursuit of increased competitiveness and bottom-line impact, pharmaceutical manufacturers face increasing pressure to fast-track technological innovation while maintaining regulatory compliance. technology initiatives.
Sales reps in the manufacturing industry face unique challenges. Competition is fierce, buyers often come to the table with preconceived notions—notions that must be adjusted to make sales—and prices continue to plummet in an attempt to win business. A strong manufacturing sales training program can help. The result?
To be a superpower globally, the UK life sciences sector must not only discover and develop medicines of the future domestically, but also manufacture a significant share in the country too, according to a new report from the Medicines Manufacturing Industry Partnership (MMIP). It provides almost 45 percent of the £36.9
They do not have biosimilar or generic competition available in the market. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. They do not qualify for any exemption (e.g.,
Traditionally, companies have sought to outsource the development and manufacture of vectors to a contract development and manufacturing organisation (CDMO). However, increasing demand from a growing market, logistics issues and manufacturing challenges all contribute to a less stable supply chain.
Influencing factors identified in the report include higher competition, competitive pricing and inflation rate, technological advancements and evolving regulatory guidelines. Enhanced interconnectivity of equipment and technologies has also put demand on manufacturing operations. These factors have led to industry 4.0
Results from CPhI’s 2022 Pharma Index survey , announced at this year’s CPhI Frankfurt, showed pharma confidence in growth , innovation and manufacturing quality has reached record highs, promising positive prospects for the industry in 2023 and beyond. Competitiveness. Germany (in second place) and the UK achieved double-digit growth.
UKRI highlighted that overall, these investments will “enhance the UK’s global competitiveness by supporting research and innovation that leads to new and disruptive biomanufacturing processes across the UK.” Curious about sustainability in pharmaceutical manufacturing and the supply chain?
To prepare for the second order effects of the IRA, one important step that we recommend for manufacturers is to clearly articulate and outline the remaining uncertainties regarding how the IRA will be implemented by CMS and identify scenarios most likely to impact their products. Acceptance and Consideration of Manufacturer Evidence.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content